Potential competitors to Amgen’s Tepezza (teprotumumab), the only approved drug therapy for thyroid eye disease (TED), keep lining up as privately held Sling Therapeutics unveiled positive Phase IIb/III on 14 January data for linsitinib, an oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor that could provide a convenience advantage in a space where the standard of care and several developmental competitors are injectable.
Sling Brings Potential Oral Competition To Amgen’s Tepezza In TED
With positive Phase IIb/III data for IGF-1r inhibitor linsitinib, privately held Sling plans to move into Phase III and compete in thyroid eye disease on convenience and safety.
More from Clinical Trials
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
More from Therapy Areas
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.